Core Viewpoint - Yidu Technology (02158) has seen a stock price increase of over 5%, currently trading at 6.06 HKD with a transaction volume of 74.9734 million HKD, following the announcement of a significant project win [1] Company Summary - Yidu Technology's subsidiary, Tianjin Happy Life Technology Co., Ltd., has won a bid for the Phase III clinical research project of the human nerve growth factor (SMR001) eye drops for Shandong Yandu Biotechnology Co., Ltd., with a total project value of approximately 55.82 million RMB [1] - The company positions itself as a driver of AI transformation in healthcare, utilizing its self-developed core algorithm engine, YiduCore, to create a "data-algorithm-scenario" closed-loop system [1] - This system enables efficient innovation and low-cost scalable applications of AI technology, empowering intelligent decision-making across the entire healthcare ecosystem, including medicine, insurance, and patients [1]

9月23日，2025中外知名企业四川行活动（以下简称四川行活动）在成都开幕。活动现场，两组数据引起记者 的注意：14——纳入主体活动现场集中签约项目共14个，投资金额359亿元，且全部为新质生产力项目；70%—— 参会企业中，产业背景与四川着力构建的"15+N"重点产业链方向高度契合的企业占比超70%。 两组数据清晰指向本次四川行活动的目标：大力引进发展新质生产力的前沿项目，扎实推进重点产业建圈强 链。 引入项目 主打新兴和未来 "今年签约落地的项目不少属于新兴产业和未来产业。"开幕式结束后，多位参会企业代表表达了相同的观 察。记者了解到，此次四川行活动期间，拟签约投资合作项目340个，投资金额2630.6亿元。其中，四川六大优势 产业项目占比超80%，新兴产业和未来产业项目占比达39%。 具身智能人形机器人制造总部基地、北京推想AI车载流动医疗西部总部及生产基地、集成电路核心设备生产 研发基地……记者梳理开幕式现场集中签约的14个代表性项目后，有一个直观的感受：向"新"力满满。 落地自贡的北京推想AI车载流动医疗西部总部及生产基地便是代表之一。"四川拥有丰富的医疗资源。我们希 望通过AI车载流动医疗装备，将 ...

"主动脉疾病死亡率，比很多癌症都更令人绝望，40%的患者没到医院就已离世，即便能够及时接受手术，欧美地区死亡率仍超17%。"香港中文大学医学院 外科学系教授、香港威尔斯亲王医院心胸外科主任黄鸿亮在接受记者采访时提及一组触目惊心的数据。 更棘手的是"漏诊魔咒"。由于主动脉疾病症状极具迷惑性，部分患者仅表现为腹痛、咳嗽、头晕，与普通感冒、肠胃炎等病症高度相似。黄鸿亮团队研究发 现，急诊室中30%的胸痛患者实际患有主动脉相关疾病，却因漏诊被当作普通病症处理，错过最佳治疗时机。"没有医生想漏诊，但主动脉疾病可能堵塞脑 部血管，症状复杂且隐蔽，再加上急诊室患者量大、诊疗时间紧张，漏诊几乎成了行业顽疾，引入AI超声诊断迫在眉睫。" 作为深耕心胸外科数十年的专家，黄鸿亮及其团队长期聚焦主动脉瘤、主动脉撕裂等高危疾病的诊疗难题，他见证了无数主动脉疾病患者与死神的博弈。他 认为，当下AI（人工智能）的飞速发展正成为这场"生死竞速"中的关键变量，也是他们破解"高死亡率、高漏诊率、诊疗资源错配"三大痛点的关键突破口。 日前，中国科学院香港创新研究院发布了其最新科研成果"聆音"EchoCare超声大模型。黄鸿亮在接受《每日经济新闻》 ...

每经记者｜甄素静 每经编辑｜魏官红 调研显示40%主动脉疾病患者未到医院便离世，30%患者在急诊中被漏诊 "主动脉就像城市里最繁忙的高速公路，负责将心脏血液输送到脑部、内脏等所有重要器官，一旦出问题，整个'交通系统'都会瘫痪。"黄鸿亮形象地比喻 道。主动脉最致命的问题，莫过于动脉瘤（血管壁膨胀形成"血肿瘤"）与主动脉撕裂，这两种情况一旦发生，短则几分钟、长则数小时，就能夺走患者生 命。 临床数据揭示了这场"生死战"的残酷。黄鸿亮团队通过长期研究发现，40%的主动脉撕裂患者在抵达医院前就因大出血或器官衰竭离世；即便顺利入院，等 待手术间隙，仍有患者因病情急转直下离世。即便是医疗水平领先的欧美国家，此类疾病的手术死亡率仍高达17%~20%，且术后有33%的患者需要再次接 受血管修复手术。 在香港地区，医疗资源分布情况加大了临床难度。黄鸿亮表示，香港公立医院中，仅3家医院具备开展主动脉疾病急诊手术的能力，其余医院若接收此类患 者，必须通过转院才能让患者获得有效救治。"从患者确诊到转院，每一分、每一秒都在消耗生存机会，很多患者没能撑到手术台。" "主动脉疾病死亡率，比很多癌症都更令人绝望，40%的患者没到医院就已离世 ...

Group 1 - Qilu Bank has established a comprehensive financial service ecosystem to support private enterprises, particularly in the marine economy sector, enhancing their operational capabilities and reducing financing barriers [1][2] - The bank has introduced innovative financial solutions, such as the "Blue Cold Chain Industry Chain Financial Solution," to address funding bottlenecks in the cold chain logistics industry, specifically for a leading enterprise in the region [2][3] - The cold storage utilization rate of the leading enterprise increased from 90% to 98%, and it became one of the busiest cold chain hubs in the Shandong Peninsula, with a daily throughput exceeding 800 tons [3] Group 2 - Qilu Bank has focused on technology finance, providing tailored financial products like "Kairong Loan" to support technology-driven enterprises, which have significant funding needs due to increased orders and R&D investments [4][5] - The bank has developed an online financing product called "Kairong e-loan," which evaluates the strength and potential of technology enterprises based on big data, effectively turning their technological capabilities into financial assets [5] - As of June, the balance of technology loans at Qilu Bank's Liaocheng branch reached 2.18 billion, reflecting a 30% increase since the beginning of the year [5] Group 3 - Qilu Bank has launched the "No Recourse Domestic Factoring (Quanshin Chain)" service to help small and micro enterprises manage their accounts receivable, providing them with efficient financing options [6][7] - The bank has successfully facilitated over 260 loans totaling more than 760 million for private enterprises through the "Quanshin Chain" product, addressing their accounts receivable financing challenges [7]

Core Insights - Yidu Technology (02158) announced that its subsidiary, Tianjin Happy Life Technology Co., Ltd., won a bid for the Phase III clinical research project of recombinant human nerve growth factor (SMR001) eye drops from Shandong Yandu Biotechnology Co., Ltd., with a total project amount of approximately RMB 55.82 million [1] Company Overview - Yidu Technology is positioned as a driver of AI medical transformation in China, with a mission to make precision medicine accessible to everyone [1] - The company develops professional, efficient, precise, and inclusive medical AI products and solutions based on its proprietary core algorithm engine, YiduCore [1] AI Medical Value Proposition - The core of AI in healthcare is to enhance the quality and efficiency of medical evidence, optimizing research, diagnosis, and treatment processes to ultimately provide safer, higher-quality, and more accessible medical services [1] - Yidu Technology aims to improve the efficiency and accessibility of medical services, equipping doctors with precise and efficient decision-making tools, shortening the distance from molecules to patients for pharmaceutical companies, and providing patients with affordable precision diagnosis and treatment [1] - The value of medical AI is reflected in the respect for individual lives and the safeguarding of health and well-being [1]

Group 1 - Core viewpoint: Furuya Medical Technology (01696) saw a stock increase of over 6%, currently trading at 5.98 HKD with a transaction volume of 10.9752 million HKD [1] - Furuya Medical Technology announced a commercial distribution cooperation agreement with Fosun Wanbang, which will provide services for the product Botulinum Toxin Type A, branded as Daxife in mainland China [1] - The annual transaction cap for this agreement is set at 17 million USD for the period from yesterday until the end of this year and the next year [1] Group 2 - The product is intended for the temporary improvement of moderate to severe frown lines caused by the activity of the glabellar muscles in adults [1] - The agreement is expected to generate additional revenue for the company [1]

Core Viewpoint - The company, Jianerkang Medical Technology Co., Ltd., is set to hold a half-year performance briefing on October 10, 2025, to discuss its operational results and financial status for the first half of 2025, allowing investors to engage in Q&A sessions [2][3][4]. Group 1: Meeting Details - The performance briefing will take place on October 10, 2025, from 11:00 AM to 12:00 PM [2][4]. - The meeting will be held at the Shanghai Stock Exchange Roadshow Center and will be conducted in an interactive online format [2][3]. - Investors can submit questions from September 25, 2025, to October 9, 2025, before 4:00 PM, through the Roadshow Center website or via the company's email [2][5]. Group 2: Company Representatives - The meeting will feature key company representatives, including Chairman and General Manager Chen Guoping, Board Secretary Liu Ping, and Chief Financial Officer Gong Xiaole [4][5]. - Adjustments to the attending personnel may occur due to special circumstances [4]. Group 3: Post-Meeting Information - After the briefing, investors can access the meeting's details and main content through the Shanghai Stock Exchange Roadshow Center [5].

Core Viewpoint - Hangzhou Bank is committed to serving the real economy and has successfully launched the "Zheke United Loan," a new financing model for technology enterprises, reflecting its long-term efforts in building a specialized technology financial service system [1] Group 1: Overview of "Zheke United Loan" - "Zheke United Loan" is guided by multiple financial and governmental bodies, aiming to address the financing challenges faced by technology enterprises throughout their lifecycle [2] - The loan program includes three sub-products: "Inclusive United Loan," "Growth United Loan," and "Leading United Loan," tailored to meet the diverse financial needs of technology enterprises at different stages [2] Group 2: Focus on Inclusive Financing - The program emphasizes inclusive finance, targeting small and micro technology enterprises that require assistance [3] - A joint service team was established between Hangzhou Bank and Industrial and Commercial Bank of China to provide tailored support to high-growth technology enterprises [3] Group 3: Growth Financing Solutions - The "Growth United Loan" has been customized for a startup medical enterprise, providing a credit line of 12 million yuan with a loan rate 26 basis points lower than the average [5] - This support has enabled the enterprise to meet its funding needs for research, production, and expansion [5] Group 4: Large Demand Financing - The "Leading United Loan" is designed for mature technology enterprises with significant funding needs, offering high credit limits and long terms [6] - A collaboration with Minsheng Bank has facilitated a project that supports a digital healthcare enterprise, enhancing its capacity for innovation and service quality [6] - The program integrates various resources to provide stable and diverse financial support for technology enterprises throughout their growth lifecycle [6]

上海建发致新医疗科技集团股份有限公司 首次公开发行股票并在创业板上市 发行结果公告 保荐人（主承销商）：中信证券股份有限公司 上海建发致新医疗科技集团股份有限公司（以下简称"建发致新"或 "发行人"）首次公开发行人民币普通股（A 股）并在创业板上市（以下简 称"本次发行"）的申请已经深圳证券交易所（以下简称"深交所"）创业 板上市委员会审议通过，并已经中国证券监督管理委员会（以下简称"中国 证监会"）同意注册（证监许可〔2025〕1337 号）。中信证券股份有限公司 （以下简称"中信证券"、"保荐人（主承销商）"或"主承销商"）担任 本次发行的保荐人（主承销商）。发行人的股票简称为"建发致新"，股票代 码为"301584"。 本次发行采用向参与战略配售的投资者定向配售（以下简称"战略配 售"）、网下向符合条件的投资者询价配售（以下简称"网下发行"）及网上 向持有深圳市场非限售 A 股股份和非限售存托凭证市值的社会公众投资者定 价发行（以下简称"网上发行"）相结合的方式进行。发行人和主承销商协 商确定本次发行的发行价格为人民币 7.05 元/股，发行股份数量为 63,193,277 股，全部为新股发行，无老股转 ...